Development of a chimeric strain of porcine reproductive and respiratory syndrome virus with an infectious clone and a Korean dominant field strain

Lee, Jung-Ah; Lee, Nak-Hyung; Lee, Sang‐Won; Park, Seung‐Yong; Song, Chang‐Seon; Choi, In‐Soo

doi:10.1007/s12275-014-4074-4

Cited by 16 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study has demonstrated that chimeric PRRS viruses harboring mixed structural genes from two different PRRSV strains can provide protection against both donor viruses [ 29 ]. A study has also reported a cross-neutralizing antibody response from a PRRSV chimera engineered to contain Korean strain-specific (LMY) structural genes in an FL12 backbone [ 30 ]. However, it has not been further evaluated in pigs.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Cross-Protective Efficacy of a Chimeric Porcine Reproductive and Respiratory Syndrome Virus Constructed Based on Two Field Strains

Shabir

Khatun

Nazki

et al. 2016

Viruses

View full text Add to dashboard Cite

One of the major hurdles to porcine reproductive and respiratory syndrome (PRRS) vaccinology is the limited or no cross-protection conferred by current vaccines. To overcome this challenge, a PRRS chimeric virus (CV) was constructed using an FL12-based cDNA infectious clone in which open reading frames (ORFs) 3–4 and ORFs 5–6 were replaced with the two Korean field isolates K08-1054 and K07-2273,respectively. This virus was evaluated as a vaccine candidate to provide simultaneous protection against two genetically distinct PRRS virus (PRRSV) strains. Thirty PRRS-negative three-week-old pigs were divided into five groups and vaccinated with CV, K08-1054, K07-2273, VR-2332, or a mock inoculum. At 25 days post-vaccination (dpv), the pigs in each group were divided further into two groups and challenged with either K08-1054 or K07-2273. All of the pigs were observed until 42 dpv and were euthanized for pathological evaluation. Overall, the CV-vaccinated group exhibited higher levels of tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and interleukin-12 (IL-12) expression and of serum virus-neutralizing antibodies compared with the other groups after vaccination and also demonstrated better protection levels against both viruses compared with the challenge control group. Based on these results, it was concluded that CV might be an effective vaccine model that can confer a broader range of cross-protection to various PRRSV strains.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the Cross-Protective Efficacy of a Chimeric Porcine Reproductive and Respiratory Syndrome Virus Constructed Based on Two Field Strains

Shabir

Khatun

Nazki

et al. 2016

Viruses

View full text Add to dashboard Cite

show abstract

“…A previous study demonstrated that chimeric PRRSV, which contained mixed structural genes from two different strains, was able to provide cross-protection against donor strains [16]. In another previous study, it was observed that a chimeric PRRSV (K418) consisting of the structural gene of the LMY strain in the FL12 backbone produced cross-protection in vitro [32]. Subsequently, the same research team created deglycosylated K418 (K418DM), which was proven to be effective and safe under experimental and field conditions [33].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the Cross-Protective Efficacy of a Chimeric PRRSV Vaccine against Two Genetically Diverse PRRSV2 Field Strains in a Reproductive Model

et al. 2021

View full text Add to dashboard Cite

Despite the routine use of porcine reproductive and respiratory syndrome (PRRS)-modified live vaccines, serious concerns are currently being raised due to their quick reversion to virulence and limited cross-protection against divergent PRRS virus (PRRSV) strains circulating in the field. Therefore, a PRRS chimeric vaccine (JB1) was produced using a DNA-launched infectious clone by replacing open reading frames (ORFs) 3–6 with those from a mixture of two genetically different PRRSV2 strains (K07–2273 and K08–1054) and ORF1a with that from a mutation-resistant PRRSV strain (RVRp22) exhibiting an attenuated phenotype. To evaluate the safety and cross-protective efficacy of JB1 in a reproductive model, eight PRRS-negative pregnant sows were purchased and divided into four groups. Four sows in two of the groups were vaccinated with JB1, and the other 4 sows were untreated at gestational day 60. At gestational day 93, one vaccinated group and one nonvaccinated group each were challenged with either K07–2273 or K08–1054. All of the sows aborted or delivered until gestation day 115 (24 days post challenge), and the newborn piglets were observed up to the 28th day after birth, which was the end of the experiment. Overall, pregnant sows of the JB1-vaccinated groups showed no meaningful viremia after vaccination and significant reductions in viremia with K07–2273 and K08–1054, exhibiting significantly higher levels of serum virus-neutralizing antibodies than non-vaccinated sows. Moreover, the JB1-vaccinated groups did not exhibit any abortion due to vaccination and showed improved piglet viability and birth weight. The piglets from JB1-vaccinated sows displayed lower viral concentrations in serum and fewer lung lesions compared with those of the piglets from the nonvaccinated sows. Therefore, JB1 is a safe and effective vaccine candidate that confers simultaneous protection against two genetically different PRRSV strains.

show abstract

“…The inactivated vaccine strain used for this study, K418/GP5DM, lacked two potential N-glycosylation sites on GP5 [ 12 ]. The virus was inactivated using binary ethylenimine, and was mixed with the Montanide IMS1313 VG adjuvant (SEPPIC, Paris, France) in a 7:3 ratio.…”

Section: Methodsmentioning

confidence: 99%

“…The aim of this study was to investigate the ability of an inactivated vaccine with the deglycosylated PRRSV in pigs reared under farm conditions. The vaccine strain used in this study was a chimeric virus consisting of structural proteins of the dominant field virus found in Korea for assessment of its application under the Korean field condition [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Augmented immune responses in pigs immunized with an inactivated porcine reproductive and respiratory syndrome virus containing the deglycosylated glycoprotein 5 under field conditions

Lee

et al. 2016

Clin Exp Vaccine Res

Self Cite

View full text Add to dashboard Cite

PurposePorcine reproductive and respiratory syndrome virus (PRRSV) leads to major economic losses in the swine industry. Vaccination is the most effective method to control the disease by PRRSV.Materials and MethodsIn this study, the efficacy of a glycoprotein (GP) 5-modified inactivated vaccine was investigated in pigs. The study was performed in three farms: farm A, which was porcine reproductive and respiratory syndrome (PRRS)-negative, farm B (PRRS-active), which showed clinical signs of PRRS but had not used vaccines, and farm C (PRRS-stable), which had a history of endemic PRRS over the past years, but showed no more clinical signs after periodic administration of modified live virus vaccine.ResultsThe inactivated vaccine induced great enhancement in serum neutralizing antibody titer, which was sufficient to protect pigs from further infections of PRRSV in a farm where pre-existing virus was circulating.ConclusionThese results indicated that vaccination with the inactivated vaccine composed of viruses possessing deglycosylated GP5 would provide enhanced protection to pigs from farms suffering from endemic PRRSV.

show abstract

Development of a chimeric strain of porcine reproductive and respiratory syndrome virus with an infectious clone and a Korean dominant field strain

Cited by 16 publications

References 32 publications

Evaluation of the Cross-Protective Efficacy of a Chimeric Porcine Reproductive and Respiratory Syndrome Virus Constructed Based on Two Field Strains

Evaluation of the Cross-Protective Efficacy of a Chimeric Porcine Reproductive and Respiratory Syndrome Virus Constructed Based on Two Field Strains

Evaluation of the Cross-Protective Efficacy of a Chimeric PRRSV Vaccine against Two Genetically Diverse PRRSV2 Field Strains in a Reproductive Model

Augmented immune responses in pigs immunized with an inactivated porcine reproductive and respiratory syndrome virus containing the deglycosylated glycoprotein 5 under field conditions

Contact Info

Product

Resources

About